Cover Image

Simultaneous assay of Mupirocin and Metronidazole in formulations using Reverse Phase-High Performance Liquid Chromatography

Sivannarayana P.*, K. Rambabu


A new reverse phase-high performance liquid chromatographic method for the assay of mupirocin and metronidazole in formulation has been developed and validated as per ICH guidelines. The present study was carried on Water’s X-bridge C-18 column (4.6 x150mm, 5μ particle size) with mobile phase containing a mixture phosphate buffer (pH 2.5) and acetonitrile in the ratio of 70:30, %v/v at a flow rate of 1.0ml/min with UV detection at 220nm in ambient column temperature. The retention times for mupirocin and metronidazole were found to be 2.153 and 3.157 min respectively with linearity in the concentration range of 20-60μg/mL for mupirocin and 10-30μg/mL for metronidazole respectively. The developed reverse phase-high performance liquid chromatographic method was found to be best suitable for pharmacokinetic studies of these mentioned drugs in formulations.


Mupirocin; Metronidazole; ICH Guidelines

Full Text:



Gould PW, Villiger JW. “Clinical and bacteriological efficacy of mupirocin (Bactroban): A new topical antibiotic”. The New Zealand medical journal 99.805 (1986):516.

Mc Carthy M and MacCulloch D. “Antibacterial activity of mupirocin (Bactroban)”. The New Zealand medical journal 100.816(1987):26.

Parenti MA, Hatfield SM and Leyden JJ. “Mupirocin: A topical antibiotic with a unique structure and mechanism of action. Clinical Pharmacology 6.10(1987):761-770.

Vizcaino-Alcaide MJ, Herruzo-Cabrera R and Rey-Calero J. “Efficacy of a broad-spectrum antibiotic (mupirocin) in an in vitro model of infected skin”. Burns 19.5(1993)392-395.

Hager WD and Rapp RP. “Metronidazole”. Obstetrics and Gynecology Clinics of North America 191992.19; 497-510.

Kaiser AB. “Antimicrobial prophylaxis in surgery”. The New England Journal of Medicine 315(1986):1129-1138.

Powell SJ, MacLeod I, Wilmot AJ and Elsdon-Dew, R. “Metronidazole in amoebic dysentery and amoebic liver abscess”. Lancet 2(1966):1329–1331.

Ueno K, Ninomiya K and Suzuki S. “Antibacterial activity of metronidazole against anaerobic bacteria”. Chemotherapy 19(1971):111–114.

Tally FP, Sutter VL and Fine gold SM. “Metronidazole versus anaerobes: in vitro data and initial clinical observations”. California Medicine 117(1972):22–26.

McGilveray IJ, Midha KK, Loo JC and Cooper JK. “The bioavailability of commercial metronidazole formulations”. International Journal of Basic & Clinical Pharmacology 16(1978):110–115

Siddiraju Ridhar, Anusha T and Sudhakar Muvvala, “Method development and validation for the simultaneous estimation of metronidazole and mupirocin by RP-HPLC in pharmaceutical dosage form”. Pharmanest-An International Journal of Advances in Pharmaceutical Sciences (2014):2519-252

Prasanna Kumar Pradhan, Jatin Patel, Mayank Patel and Mavani Dhaval. “RP-HPLC and UV spectroscopy method development and validation for simultaneous estimation of metronidazole and mupirocin in their combined dosage form”.Inventi rapid: Pharma analysis and quality assurance 5.6(2014):2519-2523.

ICH Harmonized Tripartite Guideline International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Validation of Analytical Procedures: Text and Methodolgy.2005.



  • There are currently no refbacks.

Copyright (c) 2016 International Journal of Bioassays

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.